GS-4528
/ Gilead
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
December 01, 2025
Machine learning-based identification of core regulatory genes in hepatocellular carcinoma: insights from lactylation modification and liver regeneration-related genes.
(PubMed, Front Oncol)
- "We integrated lactylation modification profiles with transcriptomic data from three murine liver regeneration datasets (GSE20426, GSE70593, GSE4528)...This work uniquely establishes lactylation as a metabolic-epigenetic bridge linking physiological regenerative pathways to oncogenesis. By leveraging liver regeneration models and machine learning, we propose the identified gene panel as dual-purpose biomarkers for HCC diagnosis and therapeutic targeting, offering new insights into the metabolic-epigenetic regulation of HCC."
Journal • Hepatocellular Cancer • Oncology • Solid Tumor • CCNA2 • CD8 • KIF2C • RACGAP1
September 04, 2025
Study of GS-4528 in Adults With Solid Tumors
(clinicaltrials.gov)
- P1 | N=182 | Active, not recruiting | Sponsor: Gilead Sciences | Recruiting ➔ Active, not recruiting
Enrollment closed • Monotherapy • Solid Tumor
September 19, 2024
Study of GS-4528 in Adults With Solid Tumors
(clinicaltrials.gov)
- P1 | N=182 | Recruiting | Sponsor: Gilead Sciences | N=132 ➔ 182
Combination therapy • Enrollment change • Metastases • Monotherapy • Oncology • Solid Tumor
June 05, 2023
Study of GS-4528 in Adults With Solid Tumors
(clinicaltrials.gov)
- P1 | N=132 | Recruiting | Sponsor: Gilead Sciences | Not yet recruiting ➔ Recruiting
Combination therapy • Enrollment open • Metastases • Monotherapy • Oncology • Solid Tumor
May 03, 2023
Study of GS-4528 in Adults With Solid Tumors
(clinicaltrials.gov)
- P1 | N=132 | Not yet recruiting | Sponsor: Gilead Sciences
New P1 trial • Oncology • Solid Tumor
1 to 5
Of
5
Go to page
1